An observational study in Hemophagocytic Lymphohistiocytoses, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Samsung Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.
Study process is as follows.
Laboratory evaluation will be done for subjects according to the following diagnostic criteria.
Diagnosis will be established if one of either 1 or 2 below is fulfilled
111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.
This study's planned enrollment of 81 is below the median of 114 across 34 observational studies indexed under Lymphohistiocytosis, Hemophagocytic.
Browse Lymphohistiocytosis, Hemophagocytic studies →Samsung Medical Center is the lead sponsor of 1,011 studies on the registry; 152 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects should fulfill the following criteria
Subjects should have at least one of the following problems
Exclusion Criteria:
Subjects should fulfill the following criteria 1. Subjects should have at least one of the following problems 1. Presence of hemophagocytosis in tissue or bone marrow 2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria 2. Age \> 18 years 3. Written informed consents Subjects receive steroids and etoposide
Drug: Steroids · Drug: Etoposide
Response
Response to steroids and etoposide
Time frame: 28 days after the 1st treatment
Progression-free survival
Time to date of progression or any kinds of death
Time frame: 3 years
Overall survival
Time to date of any kinds of death
Time frame: 3 years
Plan to share: Undecided
Started Jan 2017 (actual). Primary completion is estimated for Dec 2028, 143 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphohistiocytosis, Hemophagocytic →